827034-92-4

Upstream product

• 906651-47-6 1-tert-butyl (S)-2-{(E)-(S)-1-[(S)-1-tert-butoxycarbonyl-2-(4-but-2-ynyloxy-phenyl)-ethylcarbamoyl]-10-oxo-heptadec-2-enyl}-2-hydroxy-succinate 
• 1378531-99-7 (R)-3-((S)-1-hydroxy-2-((4-methoxybenzyl)oxy)ethyl)-3-(methylthio)dihydrofuran-2(3H)-one 
• 1378532-00-3 (3S,4S)-3-(hydroxymethyl)-5-((4-methoxybenzyl)oxy)-3-(methylthio)pentane-1,4-diol 
• 1378532-01-4 (2S,3S)-5-((tert-butyldiphenylsilyl)oxy)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-1-((4-methoxybenzyl)oxy)-3-(methylthio)pentan-2-ol 
• 1378532-02-5 tert-butyl(((2R,3S)-2-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-3-(((4-methoxybenzyl)oxy)methyl)oxiran-2-yl)methoxy)diphenylsilane 
• 744208-84-2 ((2S,3R)-3-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-3-(((tert-butyldiphenylsilyl)oxy)methyl)oxiran-2-yl)methanol 
• 744208-85-3 C₅₆H₈₂O₆Si₂ 
• 744208-86-4 C₅₉H₈₆O₆Si₂ 
• 744208-87-5 2-((4S,5S)-5-(8-(2-heptyl-1,3-dioxolan-2-yl)oct-1-en-1-yl)-4-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethanol 
• 744208-91-1 (S)-di-tert-butyl 2-((S,Z)-1-(((S)-3-(4-(but-2-yn-1-yloxy)phenyl)-1-(tert-butoxy)-1-oxopropan-2-yl)amino)-1,11-dioxooctadec-3-en-2-yl)-2-hydroxysuccinate 
• 744208-89-7 (S)-di-tert-butyl 2-hydroxy-2-((R)-1-hydroxy-11-oxooctadec-3-en-2-yl)succinate 
• 744208-88-6 (4S,5S)-tert-butyl 4-(2-(tert-butoxy)-2-oxoethyl)-5-(8-(2-heptyl-1,3-dioxolan-2-yl)oct-1-en-1-yl)-2,2-dimethyl-1,3-dioxane-4-carboxylate 
• 906651-54-5 tert-butyl (2S,3S,E)-3-(((S)-3-(4-(but-2-yn-1-yloxy)phenyl)-1-(tert-butoxy)-1-oxopropan-2-yl)carbamoyl)-11-(2-heptyl-1,3-dioxolan-2-yl)-2-hydroxy-2-(2-hydroxyethyl)undec-4-enoate 
• 827036-35-1 tert-butyl (S)-2-amino-3-(4-(but-2-yn-1-yloxy)phenyl)-propanoate hydrochloride 

Relevant academic research and scientific papers

Development of a Kilogram-Scale Synthesis of a Novel Anti-HCV Agent, CH4930808

Herein, we report the kilogram-scale synthesis of CH4930808 (1), a novel anti-hepatitis C virus agent. While pursuing improved productivity using many through-process strategies, we conducted scrupulous impurity control. Finally, we successfully developed

Stereoselective synthesis of the viridiofungin analogue NA808 from a chiral tetrahydrofuran-carboxylic acid

The viridiofungin analogue NA808 was synthesized by the stereoselective Ireland-Claisen rearrangement of dienylmethyl ester, regioselective bromolactonization of β-divinylpropanoic acid and retro-bromolactonization. +

Enantioselective synthesis of derivatives and structure-activity relationship study in the development of NA255 as a novel host-targeting anti-HCV agent

Hepatitis C virus (HCV) infection represents a serious health-care problem. Previously we reported the identification of NA255 from our natural products library using a HCV sub-genomic replicon cell culture system. Herein, we report how the absolute stereochemistry of NA255 was determined and an enantioselective synthetic method for NA255 derivatives was developed. The structure-activity relationship of the NA255 derivatives and rat pharmacokinetic profiles of the representative compounds are disclosed.

A direct catalytic asymmetric aldol reaction of α-sulfanyl lactones: Efficient synthesis of SPT inhibitors

Softly does it: The title reaction, catalyzed by a AgPF6/(R)- biphep-type ligand/DBU complex, is described (see scheme). This protocol gives efficient access to syn-configured α-sulfanyl-β-hydroxy lactones in a highly enantioselective manner. In one particular case, the sulfide group was stereospecifically replaced with a hydroxy group to afford an enantioenriched tertiary alcohol, which upon further manipulation led to a class of densely functionalized SPT inhibitors. Copyright

PROCESS FOR PRODUCING COMPOUND WITH ANTI-HCV POTENCY AND INTERMEDIATE FOR USE THEREIN

A method whereby a compound having HCV replication inhibitory activity and desired optical activity can be synthesized selectively and at high yield in a small number of steps by using a compound having a specific chiral auxiliary as a starting compound i

REMEDY FOR VIRAL DISEASE

The object of the present invention is to provide a pharmaceutical composition for preventing or treating viral infectious diseases. The compounds of the present invention have extremely potent anti-HCV activity and HCV growth inhibitory effects, and sinc